Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, …

Sep 30, 2024 · Antibody-drug conjugates (ADCs) are “biological bullets” that combine cytotoxic drugs (payloads) with antibodies through “linkers.” ADCs consist of five key elements: target, …

An antibody is linked to a small molecule via a covalent tether. A linker may be a small part of an antibody-drug conjugate, but drugmakers are finding that linker chemistry is important.

May 27, 2025 · Linker tethering payload to antibody is vital for ADC. This review provides an overview of linkers of 17 approved ADCs and recent innovations in linker design, focusing on …

Jul 1, 2025 · Antibody-drug conjugates (ADCs) 1, 2 are innovative therapeutic agents that combine monoclonal antibodies with cytotoxic drugs via chemical linkers 3, enabling precise …

Nov 4, 2025 · A monoclonal antibody (mAb): Provides target specificity by recognizing an antigen expressed primarily on tumor cells. A linker: Chemically connects the antibody to the drug and …

Dec 1, 2021 · Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the …

Antibody–drug Conjugates (ADCs) are a powerful therapeutic modality for cancer treatment. ADCs are multi-functional biologics in which a disease-targeting antibody is conjugated to an …

An antibody–drug conjugate consists of three components: [34][35] Antibody - targets the cancer cell surface and may also elicit a therapeutic response. Payload - elicits the desired …

NJ Bio, Inc., offers the following payload-linker services: Payload Synthesis and Optimization Synthesis of linkers with compatible conjugation chemistry and suitable release mechanisms …